Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis

NCT07192939 Phase 2 RECRUITING

To evaluate the efficacy and safety of HRS-9813 in subjects with pulmonary fibrosis。

Details

Lead sponsor	Guangdong Hengrui Pharmaceutical Co., Ltd
Phase	Phase 2
Status	RECRUITING
Enrolment	270
Start date	2025-10-29
Completion	2028-06

Conditions

• IPF and PPF

Interventions

• HRS-9813 capsules
• HRS-9813 capsules
• HRS-9813 capsule mimetic

Primary outcomes

• FVC as a percentage of the predicted value — The baseline period lasted until 26weeks after administration

Countries

China